Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ZXRLG)
| ADC Name |
SLV-154
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SLV-154
Click to Show/Hide
|
|||||
| Organization |
Solve Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Undisclosed
|
|||||
| Payload Target |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Sarcoma |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Breast cancer |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|
|||||
| Endometrial cancer |
1 Trials
|
|||||
| Cervical cancer |
1 Trials
|
|||||
| Urothelial cancer |
1 Trials
|
|||||
| Thyroid cancer |
1 Trials
|
|||||
| Head and neck cancer |
1 Trials
|